Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
9.73
+0.08 (0.83%)
At close: Nov 18, 2025, 4:00 PM EST
9.80
+0.07 (0.72%)
After-hours: Nov 18, 2025, 4:07 PM EST
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 45 employees as of December 31, 2024. The number of employees decreased by 31 or -40.79% compared to the previous year.
Employees
45
Change (1Y)
-31
Growth (1Y)
-40.79%
Revenue / Employee
n/a
Profits / Employee
-$1,580,311
Market Cap
529.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45 | -31 | -40.79% |
| Dec 31, 2023 | 76 | -13 | -14.61% |
| Dec 31, 2022 | 89 | -15 | -14.42% |
| Dec 31, 2021 | 104 | 31 | 42.47% |
| Dec 31, 2020 | 73 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
FULC News
- 11 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - GlobeNewsWire
- 20 days ago - Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 - GlobeNewsWire
- 27 days ago - Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics to Present at Upcoming Investor Meetings - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - GlobeNewsWire
- 4 months ago - Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire